## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.26 indicates fundamental undervaluation. Quality metrics strong (ROE 18%). Analyst consensus $391 (+14% upside).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($325.82)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. UnitedHealth stock ticks up after Barclays target hike as UNH earnings near**
- Source: ts2.tech | 20260105T170847 | Somewhat-Bullish | Relevance: 100%
- UnitedHealth shares saw an uptick after Barclays raised its price target and reiterated an "Overweight" rating, ahead of the company's full-year 2025 results and 2026 guidance release on January 27. Investors are focusing on medical-cost trends, especially the medical loss ratio, and the company's progress on operational review action plans amidst ongoing U.S. Justice Department investigations into its Medicare Advantage billing practices.

**2. Ariose Capital Management Ltd Makes New $1.38 Million Investment in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20260104T090846 | Somewhat-Bullish | Relevance: 100%
- Ariose Capital Management Ltd has made a new investment of $1.38 million in UnitedHealth Group Incorporated, purchasing 4,000 shares which now represent 0.5% of their portfolio. UnitedHealth Group (NYSE:UNH) slightly surpassed Q3 EPS expectations with revenues largely in line, maintaining a strong market presence and institutional ownership. The company offers a quarterly dividend of $2.21, and analyst ratings are mixed but generally lean towards a "Hold" with a target price around $385.54.

**3. UnitedHealth Group (UNH) Valuation Review As Profit Headwinds Meet Raised 2025 Earnings Outlook**
- Source: Simply Wall Street | 20260105T140847 | Somewhat-Bullish | Relevance: 100%
- UnitedHealth Group (UNH) is currently undervalued by 14.2%, trading at US$336.40 against a fair value of approximately US$392. This valuation comes despite a tough 2025 marked by high medical costs and Medicare Advantage pressures, with a raised full-year earnings outlook and a key January 27 update influencing sentiment. The article highlights potential risks, including tougher Medicare Advantage economics and Optum restructuring challenges, while also offering tools for investors to conduct their own analysis.

**4. Barclays Adjusts Price Target on UnitedHealth Group to $391 From $386, Maintains Overweight Rating**
- Source: marketscreener.com | 20260105T120847 | Somewhat-Bullish | Relevance: 100%
- Barclays has increased its price target for UnitedHealth Group (NYSE: UNH) to $391 from $386, while reiterating an Overweight rating on the stock. This adjustment reflects Barclays' continued positive outlook on the healthcare giant. The new price target suggests a modest but positive revision in the bank's valuation of UnitedHealth.

**5. City Holding Co. Cuts Position in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20260105T092347 | Neutral | Relevance: 100%
- City Holding Co. significantly reduced its stake in UnitedHealth Group Incorporated by 32.2% in the third quarter of 2025, selling 5,111 shares and ending with 10,752 shares valued at approximately $3.71 million. Despite this reduction, UnitedHealth Group continues to see institutional investment, with numerous other firms adjusting their positions, predominantly increasing them. The company reported strong Q3 earnings, surpassing analyst estimates, and announced a quarterly dividend of $2.21 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Barclays | $391 | $386 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 15 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +3.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.26 suggests fair value with growth premium. Forward P/E 19.3x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $309.8B |
| Beta | 0.42 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.26 |
| Forward P/E | 19.3 |
| Current P/E | 21.0 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.7% to 3.1% (+3.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.9pp (needs >4.0% for momentum thesis). MRS_5 at 2.3% confirms short-term momentum alignment. AM_20 at 3.3% shows strong absolute momentum above own 20MA. Below SMA200 (0.98x), long-term trend not supportive. MACD histogram positive (1.20), confirming momentum. OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.14% (CS: 74) | Neutral |
| RSI_14 | 60.1 | Neutral |
| MACD Histogram | 1.20 | Bullish |
| vs SMA20 | 1.033x | Above |
| vs SMA50 | 1.030x | Above |
| vs SMA200 | 0.984x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $342.14
- **Stop Loss:** $325.82 (4.8% risk)
- **Target:** $374.78 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 52
- **Position Value:** $17,791.28
- **Portfolio %:** 17.79%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*